Atara Biotherapeutics, Inc. (ATRA) stock
ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.70−0.23 (-2.90%)
Close on Nov 13, 2026Market cap $77.29MP/E –Yield –
Atara Biotherapeutics cash
Cash and short-term investments held at the end of each period.
Atara Biotherapeutics's cash was $9.90M at Sep 30, 2026. For fiscal 2025 it was $8.50M, down 80.1% from the year before. Over ten years it grew -30.4% a year on average. The highest annual figure on record is $502.05M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.50M | -80.1% |
| FY2024 | Dec 31, 2024 | $42.64M | -17.8% |
| FY2023 | Dec 31, 2023 | $51.87M | -78.7% |
| FY2022 | Dec 31, 2022 | $242.97M | -34.8% |
| FY2021 | Dec 31, 2021 | $372.46M | -25.8% |
| FY2020 | Dec 31, 2020 | $502.05M | +92.7% |
| FY2019 | Dec 31, 2019 | $260.50M | -16.2% |
| FY2018 | Dec 31, 2018 | $311.03M | +85.7% |
| FY2017 | Dec 31, 2017 | $167.49M | -34.5% |
| FY2016 | Dec 31, 2016 | $255.88M | -20.2% |
| FY2015 | Dec 31, 2015 | $320.68M | +208.0% |
| FY2014 | Dec 31, 2014 | $104.12M | +101.7% |
| FY2013 | Dec 31, 2013 | $51.62M | +1126.9% |
| FY2012 | Dec 31, 2012 | $4.21M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.90M | -27.8% |
| Q2 FY2026 | Jun 30, 2026 | $9.90M | -55.7% |
| Q1 FY2026 | Mar 31, 2026 | $8.36M | -40.2% |
| Q4 FY2025 | Dec 31, 2025 | $8.50M | -80.1% |
| Q3 FY2025 | Sep 30, 2025 | $13.71M | -79.6% |
| Q2 FY2025 | Jun 30, 2025 | $22.32M | -37.0% |
| Q1 FY2025 | Mar 31, 2025 | $13.99M | -69.8% |
| Q4 FY2024 | Dec 31, 2024 | $42.64M | -17.8% |
| Q3 FY2024 | Sep 30, 2024 | $67.34M | -34.3% |
| Q2 FY2024 | Jun 30, 2024 | $35.44M | -77.0% |
| Q1 FY2024 | Mar 31, 2024 | $46.39M | -77.4% |
| Q4 FY2023 | Dec 31, 2023 | $51.87M | -78.7% |
| Q3 FY2023 | Sep 30, 2023 | $102.55M | -61.6% |
| Q2 FY2023 | Jun 30, 2023 | $153.79M | -53.8% |
| Q1 FY2023 | Mar 31, 2023 | $205.55M | -32.2% |
| Q4 FY2022 | Dec 31, 2022 | $242.97M | -34.8% |
| Q3 FY2022 | Sep 30, 2022 | $266.75M | -25.6% |
| Q2 FY2022 | Jun 30, 2022 | $332.66M | -11.2% |
| Q1 FY2022 | Mar 31, 2022 | $303.16M | -30.6% |
| Q4 FY2021 | Dec 31, 2021 | $372.46M | -25.8% |
| Q3 FY2021 | Sep 30, 2021 | $358.64M | +9.1% |
| Q2 FY2021 | Jun 30, 2021 | $374.77M | +7.4% |
| Q1 FY2021 | Mar 31, 2021 | $436.56M | +102.1% |
| Q4 FY2020 | Dec 31, 2020 | $502.05M | +92.7% |
| Q3 FY2020 | Sep 30, 2020 | $328.58M | +15.6% |
| Q2 FY2020 | Jun 30, 2020 | $349.11M | +82.3% |
| Q1 FY2020 | Mar 31, 2020 | $216.03M | -9.6% |
| Q4 FY2019 | Dec 31, 2019 | $260.50M | -16.2% |
| Q3 FY2019 | Sep 30, 2019 | $284.32M | -22.3% |
| Q2 FY2019 | Jun 30, 2019 | $191.53M | -54.2% |
| Q1 FY2019 | Mar 31, 2019 | $238.94M | -41.5% |
| Q4 FY2018 | Dec 31, 2018 | $311.03M | +85.7% |
| Q3 FY2018 | Sep 30, 2018 | $365.94M | +81.5% |
| Q2 FY2018 | Jun 30, 2018 | $418.41M | +91.7% |
| Q1 FY2018 | Mar 31, 2018 | $408.72M | +76.1% |
| Q4 FY2017 | Dec 31, 2017 | $167.49M | -34.5% |
| Q3 FY2017 | Sep 30, 2017 | $201.62M | – |
| Q2 FY2017 | Jun 30, 2017 | $218.29M | – |
| Q1 FY2017 | Mar 31, 2017 | $232.04M | – |
| Q4 FY2016 | Dec 31, 2016 | $255.88M | – |
See a number that looks wrong?